help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 62, No. 4 778-782
doi:10.1210/jcem-62-4-778
Copyright © 1986 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by AGNER, T.
Right arrow Articles by DJURSING, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by AGNER, T.
Right arrow Articles by DJURSING, H.

Increased Dopaminergic Activity Inhibits Basal and Metoclopramide- Stimulated Prolactin and Thyrotropin Secretion*

TOVE AGNER, CLAUS HAGEN, ANDERS N. ANDERSEN and HENNING DJURSING

Department of Internal Medicine and Endocrinology, Herlev Hospital, University of Copenhagen 2730 Herleu Department of Obstetrics and Gynecology, Rigshospitalet, University of Copenhagen 2100 Copenhagen; Hvidovre Hospital, University of Copenhagen 2650 Hvidovre, Denmark

Address all correspondence and requests for reprints to: Dr. Claus Hagen, Department of Internal Medicine and Endocrinology, Herlev Hospital, 2730 Herlev, Denmark.

The influence of physiological to pharmacological doses of dopamine (DA) on basal and metoclopramide(MTC)-stimulated PRL and TSH secretion was studied in 11 regularly menstruating women between days 3 and 8 of the cycle. In groups of 6, the women received 5-h infusions of either 5% glucose or DA in a solution of 5% glucose at a rate of 12–16ml/h, adjusted according to weight. Infusion rates of DA were 0.04 µg/kg·min (low), 0.4 µg/kg·min (medium), and 4.0 µg/kg·min (high). After 3 h of infusion, 10 mg MTC were given iv. Blood samples were collected every 15 min from 1 h before to 2 h after the infusion, for a total of 8 h, for measurements of PRL and TSH.

The mean serum PRL concentrations declined significantly (P < 0.05) during DA infusions to nadir values of 62 ± 5% (± SEM; low), 43 ± 3% (medium), and 43 ± 6% (high) of the basal levels, whereas basal TSH levels declined significantly, to 64 ± 5% of basal levels (P < 0.05), during both the medium and high dose DA infusions. On paired comparisons, the hormone responses to MTC were lower (P < 0.05) during the infusion of high dose DA (PRL, 2286 ± 495% vs. 891 ± 328%; TSH, 100 ± 43% vs. 60 ± 15%), but were not changed when MTC was given during the low and medium doses of DA. A rebound phenomenon was found for PRL (P < 0.05) after the medium and high doses of DA and for TSH (P < 0.05) after the high dose.

These results indicate that doses of DA considered physiological inhibit PRL and TSH secretion and larger doses inhibit their responses to the DA antagonist MTC.

* This work was supported by grants from the Danish Medical Research Council, Gerda and Aage Haensch's Foundation, and P. Carl Petersens Foundation.

Received September 16, 1985.




This article has been cited by other articles:


Home page
NEJMHome page
M. I. Surks and R. Sievert
Drugs and Thyroid Function
N. Engl. J. Med., December 21, 1995; 333(25): 1688 - 1694.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society